<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Oxaliplatin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00526</strong>&#160; (APRD00186)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin&#174;.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00526/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00526/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00526.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00526.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00526.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00526.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00526.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00526">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Diaminocyclohexane Oxalatoplatinum</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>L-OHP</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oxalatoplatin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oxalatoplatinum</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Eloxatin</td><td>Sanofi-Aventis</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents">Antineoplastic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>61825-94-3</td></tr><tr><th>Weight</th><td>Average: 395.276<br>Monoisotopic: 395.044481331</td></tr><tr><th>Chemical Formula</th><td>C<sub>8</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub>Pt</td></tr><tr><th>InChI Key</th><td>DWAFYCQODLXJNR-BNTLRKBRSA-L</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+4/p-2/t5-,6-;;/m1../s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3aR,7aR)-octahydro-2',5'-dioxaspiro[cyclohexa[d]1,3-diaza-2-platinacyclopentane-2,1'-cyclopentane]-3',4'-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organonitrogen Compounds</td></tr><tr><th>Class</th><td>Amines</td></tr><tr><th>Subclass</th><td>Polyamines</td></tr><tr><th>Direct parent</th><td>Polyamines</td></tr><tr><th>Alternative parents</th><td>Metalloheterocyclic Compounds; Carboxylic Acids and Derivatives</td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td>This compound belongs to the polyamines. These are compounds containing more than one amine group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. </td></tr><tr><th>Pharmacodynamics</th><td>Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. </td></tr><tr><th>Mechanism of action</th><td>Oxaliplatin undergoes nonenzymatic conversion to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and transcription. Cytotoxicity is cell-cycle nonspecific. </td></tr><tr><th>Absorption</th><td>Bioavailability is complete following intravenous administration. When a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m^2 is given, the peak serum concentration was 0.814 mcg/mL. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>440 L [single 2-hour IV infusion at dose of 85 mg/m^2]<br>
At the end of a 2-hour infusion of oxaliplatin, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine.</li>
</ul></td></tr><tr><th>Protein binding</th><td>Plasma protein binding of platinum (active metabolite) is irreversible and is greater than 90%, primarily to albumin and gamma-globulins. It is also irreversibly binds to erythrocytes. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. There is no evidence of cytochrome P450-mediated metabolism in vitro.</p></td></tr><tr><th>Route of elimination</th><td>The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of oxaliplatin, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%.</td></tr><tr><th>Half life</th><td>The decline of ultrafilterable platinum levels following oxaliplatin administartion is triphasic, with two distribution phases: t1/2&#945;; 0.43 hours and t1/2&#946;; 16.8 hours. This is followed by a long terminal elimination phase that lasts 391 hours (t1/2&#947;). </td></tr><tr><th>Clearance</th><td><ul>
	<li>10 &#8211; 17 L/h [renal clearance]</li>
</ul></td></tr><tr><th>Toxicity</th><td>There have been five cases of oxaliplatin overdose reported. One patient received two 130 mg/m2 doses of oxaliplatin (cumulative dose of 260 mg/m<sup>2</sup>) within a 24-hour period. The patient experienced Grade 4 thrombocytopenia (3) without any bleeding, which resolved. Two other patients were mistakenly administered oxaliplatin instead of carboplatin. One patient received a total oxaliplatin dose of 500 mg and the other received 650 mg. The first patient experienced dyspnea, wheezing, paresthesia, profuse vomiting and chest pain on the day of administration. She developed respiratory failure and severe bradycardia, and subsequently did not respond to resuscitation efforts. The other patient also experienced dyspnea, wheezing, paresthesia, and vomiting. Most common adverse reactions (incidence &#8805; 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8638</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7667</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6453</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5056</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9332</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9289</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8846</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8094</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6064</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8403</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8686</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8997</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8189</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8337</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9872</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6034
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.938
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9796
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3765 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8879
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.938
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li>
<li>App pharmaceuticals llc</li>
<li>Ebewe pharma ges mbh nfg kg</li>
<li>Fresenius kabi oncology plc</li>
<li>Hospira inc</li>
<li>Hospira worldwide pty</li>
<li>Sun pharma global inc</li>
<li>Teva parenteral medicines inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.ebewe.at">Ebewe Pharma</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, for solution</td><td>Intravenous</td><td>50 mg, 100 mg</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>50 mg/10 mL; 100 mg/20 mL; 200 mg/40 mL  </td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Oxaliplatin 100 mg vial</td><td>1650.0USD</td><td>vial</td></tr><tr><td>Oxaliplatin 50 mg vial</td><td>825.0USD</td><td>vial</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5420319</td><td>1997-02-09</td><td>2017-02-09</td></tr><tr><td>United States</td><td>5290961</td><td>1993-01-12</td><td>2013-01-12</td></tr><tr><td>Canada</td><td>2196922</td><td>2004-06-01</td><td>2015-08-07</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.24e+01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>0.04</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.73</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-1.5</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>5.88</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>76.66</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>65.92</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>21.29</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Masazumi Eriguchi, &#8220;Liposome preparations containing oxaliplatin.&#8221; U.S. Patent US20040022842, issued February 05, 2004.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20040022842&amp;tbm=pts" target="_blank">US20040022842 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Pasetto LM, D&#8217;Andrea MR, Rossi E, Monfardini S: Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. Epub 2006 Jun 27. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16806962">Pubmed</a></li>
	<li>Graham J, Mushin M, Kirkpatrick P: Oxaliplatin. Nat Rev Drug Discov. 2004 Jan;3(1):11-2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14756144">Pubmed</a></li>
	<li><span class="caps">FDA</span> label</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D01790" target="_blank">D01790 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6857599" target="_blank">6857599 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46509083" target="_blank">46509083 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.8062727.html" target="_blank">8062727 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=31941" target="_blank">31941 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL414804" target="_blank">CHEMBL414804 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000062" target="_blank">DAP000062 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA131285527" target="_blank">PA131285527 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/eloxatin.htm" target="_blank">http://www.rxlist.com/cgi/generic/eloxatin.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/oxaliplatin.html" target="_blank">http://www.drugs.com/cdi/oxaliplatin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Oxaliplatin" target="_blank">Oxaliplatin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L01XA03<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L01#L01">L01 &#8212; ANTINEOPLASTIC AGENTS</a></li><li><a href="/atc/L01X#L01X">L01X &#8212; OTHER ANTINEOPLASTIC AGENTS</a></li><li><a href="/atc/L01XA#L01XA">L01XA &#8212; Platinum compounds</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>10:00</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00526.pdf?1265922796">show</a>(2.35 MB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00526.pdf?1265922736">show</a>(38.4 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Increases toxicity through pharmacodynamic synergism. Additive myelosuppression.</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>Administration of Topotecan after Oxaliplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>